PRME vs. HLVX, ALLO, VALN, MESO, NVAX, FATE, ALEC, CABA, CRGX, and TSHA
Should you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include HilleVax (HLVX), Allogene Therapeutics (ALLO), Valneva (VALN), Mesoblast (MESO), Novavax (NVAX), Fate Therapeutics (FATE), Alector (ALEC), Cabaletta Bio (CABA), CARGO Therapeutics (CRGX), and Taysha Gene Therapies (TSHA). These companies are all part of the "biological products, except diagnostic" industry.
Prime Medicine (NYSE:PRME) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.
HilleVax's return on equity of -48.17% beat Prime Medicine's return on equity.
Prime Medicine received 1 more outperform votes than HilleVax when rated by MarketBeat users. However, 100.00% of users gave HilleVax an outperform vote while only 69.23% of users gave Prime Medicine an outperform vote.
70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 86.4% of HilleVax shares are held by institutional investors. 24.3% of Prime Medicine shares are held by company insiders. Comparatively, 29.3% of HilleVax shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
HilleVax is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.
In the previous week, Prime Medicine had 8 more articles in the media than HilleVax. MarketBeat recorded 11 mentions for Prime Medicine and 3 mentions for HilleVax. HilleVax's average media sentiment score of 1.01 beat Prime Medicine's score of 0.33 indicating that HilleVax is being referred to more favorably in the news media.
Prime Medicine currently has a consensus price target of $16.89, indicating a potential upside of 251.85%. HilleVax has a consensus price target of $30.67, indicating a potential upside of 139.40%. Given Prime Medicine's higher probable upside, analysts plainly believe Prime Medicine is more favorable than HilleVax.
Prime Medicine has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.
Summary
HilleVax beats Prime Medicine on 8 of the 15 factors compared between the two stocks.
Get Prime Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prime Medicine Competitors List
Related Companies and Tools
